Angitia raises $120M series C to fund trio of musculoskeletal trials jwaldron Wed, 12/11/2024 - 09:09.: Less than a year after completing a series B extension round, Angitia Biopharmaceuticals has set its sights even higher with a $120 million series C that the biotech will use to push its three musculoskeletal candidates through ongoing trials. Bain Capital Life Sciences led the financing, with new investor Janus Henderson joining previous backers OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital and Elikon Venture.